Canakinumab

Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin[1][2].

Product Specifications

CAS Number

[914613-48-2]

Product Name Alternative

Ilaris; ACZ 885

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/canakinumab.html

Purity

99.64

Solubility

10 mM in DMSO

Smiles

[Canakinumab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]Dhimolea E. Canakinumab. MAbs. Epub 2010 Jan 15. |[2]Rondeau JM, et al. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs. 2015;7 (6) :1151-60.